Articles
Difficult issues in pharma going global (part I)

Difficult issues in pharma going global (part I)

In the first piece of a two part article, Faiz Kermani looks at the emergence of clinical trial activity in emerging markets and explores some of the ethical issues. Although the economic downturn has had a negative impact, the global pharmaceutical market is still experiencing strong growth...

Articles
Biosimilars

Biosimilars

As generics companies ramp up their facilities and a raft of biologics face patent expiry, Capgemini takes a look at the landscape for biosimilars and what the future may hold. The generics of the biologics world offer potentially sizeable cost benefits to payers – but first some conflicts must be resolved...

Articles
What Are IDEAs Made Of: Strategy

What Are IDEAs Made Of: Strategy

In the first installment of WAIMO for 2010, Mike Rea notices everyone is talking about their new strategy and asks what this word really means. What is ‘Strategy’? Seriously. Ask the question of your strategy consultants. If they don’t, at some point in their dissembling, say something about making better decisions, those are some pretty dumb consultants...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. FDA nominee Overton dodges questions on Trump influence
  2. Australia starts probe into AI infiltration of Medicare
  3. Lilly forges $3.35bn alliance with China's InnoCare
  4. Telix to buy radiopharma rival ITM for $1.65bn upfront
  5. Advocacy group pokes holes in Trump's MFN pricing claims

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more